Cancer Genomic Review: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Cancer Genomic Review

Cancer Genomic Review represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Cancer Genomic Review Recommended?

• Patients with NGS genomic reports (FoundationOne, Guardant360, Tempus, Oncotype DX) needing expert clinical review.

• Patients with strong family history of breast, ovarian, colon, or pancreatic cancer seeking genetic review.

• Cancer patients progressing on targeted kinase inhibitors requiring resistance mutation analysis.

• Patients seeking tumor-agnostic targeted therapies or precision oncology second opinions.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: Clinical History & Data Ingestion

Review of patient's clinical trajectory, histology blocks, and existing NGS / molecular test results.

Step 2: Variant Annotation & Evidence Curation

Bioinformatic variant classification determining pathogenicity and tier-1 actionable targets.

Step 3: Targeted Drug Matching

Matching actionable genomic alterations with targeted therapies, clinical trials, or immunotherapies.

Step 4: Actionable Report & Family Counseling

Formulation of clear clinical action report and family cascade genetic counseling if germline mutation found.

Director's Signature Innovation: Specialist Cancer Genomic & Molecular Pathology Review

Dr. Neha Gupta provides expert Cancer Genomic Reviews and Molecular Tumor Board analyses for complex genetic sequencing reports. Translating raw Next-Generation Sequencing (NGS) data, actionable tier-1 somatic mutations, fusion transcripts, copy-number amplifications, and hereditary germline risk variants (BRCA1/2, PALB2, MSH2/MLH1 Lynch Syndrome) into clear clinical action plans, patients receive precise guidance on off-label targeted drugs, clinical trials, and family cascade genetic screening.

✔ Expert Genomic Report Interpretation: Decodes complex NGS variants of uncertain significance (VUS)

✔ Acquired Resistance Mutation Analysis: Identifies secondary mutations (e.g. EGFR C797S, ESR1) after TKI failure

✔ Hereditary Germline Risk Counseling: Pre-test and post-test genetic counseling for family risk

✔ Biomarker-Driven Clinical Pathways: Tailored targeted and immunotherapy roadmaps for refractory cancers

Recovery Timeline & Functional Milestones

Phase 1: Genomic Data Ingestion (Day 1 – 3)

Submission and clinical review of outside NGS reports, pathology blocks, and cancer history.

Phase 2: Variant Annotation & Curation (Day 4 – 7)

Molecular Tumor Board bioinformatic analysis, cross-referencing global variant databases (ClinVar, OncoKB).

Phase 3: Targeted Action Roadmap (Day 7+)

Comprehensive written genomic roadmap consultation and targeted prescription by Dr. Neha Gupta.

Frequently Asked Clinical Questions (FAQs)

Why is an expert genomic review necessary after getting an NGS report?

NGS reports contain complex bioinformatics data listing hundreds of gene variants. An experienced medical oncologist like Dr. Neha Gupta distinguishes true 'driver' mutations that have approved targeted drugs from harmless bystander mutations, ensuring patients receive the exact targeted therapy that will work.

How does genomic review help when cancer becomes resistant to targeted drugs?

When cancer begins to grow again during targeted therapy, it has developed new 'resistance mutations'. Repeating a liquid biopsy or genomic panel reveals the new resistance mechanism, allowing Dr. Neha Gupta to switch to a next-generation targeted drug (e.g. 3rd-generation TKIs).

Is Cancer Genomic Review covered under Ayushman Bharat?

Yes, genomic reviews, molecular consultations, liquid biopsy workups, and targeted therapy planning at Grover Hospital Bathinda are covered 100% cashless under PM-JAY Ayushman Bharat and 30+ private TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Cancer Genomic Review is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.